PKM 011
Alternative Names: PKM-011Latest Information Update: 07 Jun 2024
At a glance
- Originator PK MED
- Class Antirheumatics
- Mechanism of Action Tubulin polymerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Osteoarthritis
Most Recent Events
- 27 May 2024 PKM 01 is available for licensing as of 27 May 2024. https://www.pk-med.com/partnering (PK MED pipeline, May 2024)
- 27 May 2024 Preclinical trials in Osteoarthritis in France (Intra-articular) prior to May 2024 (PK MED pipeline, May 2024)